Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International...
Transcript of Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International...
![Page 1: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/1.jpg)
Catapano Alberico A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Cardiovascular (2014)
- Esteve : Cardiovascular (2014)
- Merck Sharp & Dohme : Cardiovascular (2014-2015-2016)
- Kowa : Cardiovascular (2014-2015-2016)
- Astra Zeneca : Cardiovascular (2014-2016)
- Pfizer : Cardiovascular (2014-2016)
- Sanofi Aventis : Cardiovascular (2014-2016)
- Aatra Zeneca : Cardiovascular (2015)
- Recordati International : Cardiovascular (2015-2016)
- Amgen Inc : Cardiovascular (2016)
- Aegerion : Cardiovascular (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Cardiovascular (2015)
- Pfizer : Cardiovascular (2015)
- Sanofi Aventis : Cardiovascular (2015)
- Aegerion : Cardiovascular (2015)
D - Research funding (departmental or institutional).- Pfizer : Cardiovascular (2015-2016)
- Sanofi Aventis : Cardiovascular (2015-2016)
- Merck Sharp & Dohme : Cardiovascular (2015-2016)
Chapman John A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Lilly : dyslipidemia (2014)
- Merck Sharp & Dohme : dyslipidemia (2014)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 2: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/2.jpg)
Chapman John - Kowa : dyslipidemia (2014)
- cerenis : HDL (2014)
- Amgen : hypercholesterolemia (2014)
- Sanofi Aventis : hypercholesterolemia (2014)
- Regeneron : hypercholesterolemia (2014)
- Astra Zeneca : hypertriglyceridemia (2014)
- Unilever : nutraceuticals (2014)
- Unilever : human Nutrition and CVD (2015)
- Kowa : lipid lowering and CVD (2015)
- MSD : lipid lowering and CVD (2015)
- Astrazeneca : lipid lowering, dyslipidemia and CVD (2015)
- Amgen : PCSK9 inhibition (2015)
- Sanofi-Regeneron : PCSK9 inhibition (2015)
- Servier : Atherosclerotic vascular disease (2016)
- Unilever : Lipid lowering (2016)
- Amgen : Lipid lowering therapies (2016)
- Sanofi-Regeneron : Lipid lowering therapies (2016)
D - Research funding (departmental or institutional).- Kowa : dyslipidemia (2014)
- Pfizer : diabetic dyslipidemia (2014-2015)
- Kowa : Lipid lowering, dyslipidemia and CVD (2015)
- Pfizer : Statins (2016)
- Kowa : Statins (2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 3: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/3.jpg)
Cooney Marie Therese Nothing to be declared (2014-2015-2016)
De Backer Guy Nothing to be declared (2014-2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Lipid lowering drugs (2015)
- Sanofi Aventis : Lipid lowering drugs (2015)
Drexel Heinz A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck and others : diabetes, hypertension, lipids (2014-2015-2016)
Graham Ian Maklim A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Advisory Board (2014-2015)
- Merck Sharp & Dohme : CVD risk factor audit (2014-2015)
- MSD : Prevention and risk assessment (2016)
D - Research funding (departmental or institutional).- Merck Sharp & Dohme : CVD risk factor audit (2014)
E - Research funding (personal).- World Health Organisation : Co-Chair of Expert Advisory Group developing a new CVD risk estimation system (2015)
Hoes Arno B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We
perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)
- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2014)
D - Research funding (departmental or institutional).- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We
perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 4: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/4.jpg)
Hoes Arno - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2015-2016)
Jennings Catriona Sian Nothing to be declared (2014-2015-2016)
Landmesser Ulf A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Advisory Board, Speakers fee (2014)
- Sanofi Aventis : Advisory Board, Speakers fee (2014)
- MSD : Advisory Board, Speakers fee (2014)
- Roche Pharma : Research grant, Advisory Board (2014)
- Pfizer : Research grant, Speakers fee (2014)
- St. Jude : Advisory Board fees (2015-2016)
- Amgen : Speaker fees (2015-2016)
- Pfizer : Speaker fees (2015-2016)
- Sanofi Aventis : Speaker fees (2015-2016)
- Berlin Chemie AG : Speaker fees (2015-2016)
- Roche Pharma : Speaker fees (2015-2016)
- MSD : Speaker fees, Advisory Board fees (2015-2016)
- Boehringer-Ingelheim : Speaker fees (2016)
Pedersen Terje A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : Lipid lowering drugs (2014)
- Amgen : PCSK9 inhibitor (under deveelopment) (2014)
- Amgen : Cholesterol lowering (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 5: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/5.jpg)
Pedersen Terje - Merck Sharp & Dohme : Cholesterol lowering (2015-2016)
- Sanofi Aventis : Cholesterol lowering (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : Lipid lowering drugs (2014)
- Amgen : PCSK9 inhibitor (under development) (2014)
- Merck Sharp & Dohme : Cholesterol lowering (2015)
- Amgen : Cholesterol lowering (2015-2016)
D - Research funding (departmental or institutional).- Amgen : Cholesterol lowering (2016)
- Merck Sharp & Dohme : Cholesterol lowering (2016)
Reiner Zeljko Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Synageva : LAL-D (2014)
- Sanofi Aventis : PCSK9 inihibitor (2014)
- Sanofi Aventis : PCSK9 inhibitor (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Mylan : antilipemics (2015)
D - Research funding (departmental or institutional).- Sanofi Aventis : mipomersen (2014)
Riccardi Gabriele A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : diabetes (2014-2015-2016)
- Takeda Pharmaceuticals : diabetes (2014-2015-2016)
- Aventis : diabetes (2014-2015-2016)
- Barilla Center for food and nutrition Foundation : nutrition (2014-2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Barilla Food Company : nutrition (2014-2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 6: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/6.jpg)
Riccardi Gabriele D - Research funding (departmental or institutional).- Barilla Food Company : nutrition (2014-2015-2016)
Taskinen Marja-Riitta A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : PCSK9 anti-sense (2014)
- Chiesi Pharma : Glybera (2014-2015-2016)
- Amgen : PCSK9 anti-sense (2014-2015-2016)
- Sanofi Aventis : PCSK9 anti-sense (2014-2015-2016)
- Astra Zeneca : Rosuvastatin (2014-2015-2016)
D - Research funding (departmental or institutional).- Merck Sharp & Dohme : CETP inhibitor (2014-2015-2016)
- Sanofi Aventis : PCSK9 anti-sense (2014-2015-2016)
- Novo-Nordisk : GLP1-analogue (2015-2016)
Tokgozoglu Lale A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Kowa : dyslipidemia (2014)
- Menarini-İE : coronary artery disease (2014-2015)
- Daiichi Sankyo : antiplatelet (2014-2015-2016)
- Sanofi Aventis : antiplatelet,lipid (2014-2015-2016)
- GlaxoSmithKline : antithrombotic (2014-2015-2016)
- Abbott : dyslipidemia (2014-2015-2016)
- Astra Zeneca : dyslipidemia, hypertension,antiplatelet,pulmonary hypertension (2014-2015-2016)
- Novartis : heart failure (2014-2015-2016)
- Servier : hypertension (2014-2015-2016)
- Amgen : lipid (2014-2015-2016)
- Merck Sharp & Dohme : lipid (2014-2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 7: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/7.jpg)
Tokgozoglu Lale - Aegerion : lipid (2014-2015-2016)
- Pfizer : lipids (2014-2015-2016)
- Bayer : pulmonary htn (2014-2015-2016)
- Actelion : pulmonary hypertension (2014-2015-2016)
- Boehringer-Ingelheim : thrombosis (2014-2015-2016)
- Mylan : dyslipidemia (2015-2016)
Verschuren Monique Nothing to be declared (2014-2015-2016)
Vlachopoulos Charalambos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Perindopril (2014)
- Bayer : Rivaroxaban (2014)
- Medtronic : Stents (2014)
- Pfizer : Apixaban (2014-2015)
- OMRON Healthcare : Hypertension (2014-2015)
- Astra Zeneca : Ticagrelor (2014-2015)
- Boehringer-Ingelheim : Dabigatran (2014-2015-2016)
- Merck Sharp & Dohme : Ezetimibe (2014-2015-2016)
- PharmaSwiss : Hypertension (2014-2015-2016)
- Menarini : Angina (2015)
- ELPEN : Hypertension (2015)
- Merck Serono : Hypertension-Arrhythmias (2015)
- Amgen : Dyslipidemia (2015-2016)
- Angelini : Dyslipidemia (2015-2016)
- Menarini : Erectile Dysfunction (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 8: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/8.jpg)
Vlachopoulos Charalambos - Novartis : Hypertension (2015-2016)
- Sanofi Aventis : Hypertension (2015-2016)
- Servier : Hypertension-Dyslipidemia (2015-2016)
- Menarini : Angina - Erectile Dysfunction (2016)
- Mylan : Dyslipidemia (2016)
E - Research funding (personal).- Bayer : Hormone Replacement (2016)
Wiklund Olov A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : cardiovascular prevention (2014)
- Boehringer-Ingelheim : Cardiovascular prevention (2014-2015)
- Astra Zeneca : Cardiovascular prevention (2014-2015-2016)
- Amgen Inc : cardiovascular prevention (2014-2015-2016)
- Merck Sharp & Dohme : cardiovascular prevention (2014-2015-2016)
- Sanofi Aventis : vardiovascular prevention (2016)
D - Research funding (departmental or institutional).- Quintiles : Diabetes (2014)
- Astra Zeneca : Basic cardiovascular (2014-2015)
- DuPont : Cardiovascular (2014-2015)
- Cebix inc : Diabetes (2014-2015)
- Sanof-Aventis : Cartdiovascular (2015)
Wood David Allan Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Lipid modification (2014)
- Merck Sharp & Dohme : Niacin - Lipid modification (2014)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 9: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/9.jpg)
Wood David Allan - CME project of ESC and Irish Cardiac Society : Stable CAD / EA IV (2014)
- Amgen : Lipid lowering (2015)
- Astra Zeneca : Lipid lowering (2015)
- Ferrer Internacional : Polypill (2015)
D - Research funding (departmental or institutional).- European Society of Cardiology : EUROASPIRE IV (2014)
Zamorano Gomez Jose Luis
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Philips : 3D echo (2014)
- Toshiba medical imaging : fusion imaging 3D echo CT (2014)
- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)
- MSD : CV risk factors (2014-2015)
- Abbott : Lecturing (2015)
- Pfizer : Lecturing (2015)
- Sorin Group : Respicardia echo protocol (2015)
- Philips : 3D Echocardiography. (2016)
- Servier : Clinical case presentation during ESC Cong 2016 (2016)
- Pfizer : speaker CV risk factors. (2016)
- MSD : speaker. CV risk factors (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Siemens Healthcare : 3d echo software and free style echo (2014-2015)
- Toshiba medical imaging : Fusion Imaging (2015)
D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)
- Novartis : Clinical trial (2014-2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 10: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/10.jpg)
Zamorano Gomez Jose Luis
- Ikaria : Clinical trial (2014-2015)
- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)
- Abbott : Epidemiology study of Mitral regurgitation (2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 11: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/11.jpg)
Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Thermo Fischer Scientific : Cardiac markers (2015)
- Vifor International : Heart failure (2015)
- Astra Zeneca : Platelet inhibition (2015)
- Astra Zeneca : Antiplatelet treatment (2016)
Badimon Lina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Lipids (2015-2016)
- Burson Masteller : Nutrition (2015-2016)
- Astra Zeneca : Thrombosis (2015-2016)
D - Research funding (departmental or institutional).- Astrazeneca : Thrombosis (2015-2016)
Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Anticoagulation (2015-2016)
- Daiichi Sankyo : Anticoagulation (2015-2016)
- Pfizer : Anticoagulation (2015-2016)
- Merck Sharp & Dohme : Dyslipemia (2015-2016)
- Bayer : Anticoagulation (2016)
Benlamin Hisham Nothing to be declared (2015-2016)
Boren Jan B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Metabolism (2015-2016)
- Eli Lilly : Metabolism (2015-2016)
- Sanofi Aventis : Metabolism (2015-2016)
- MSD : Metabolism (2015-2016)
- NovoNordisk : Metabolism (2015-2016)
D - Research funding (departmental or institutional).- Astra Zeneca : Metabolism (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 12: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/12.jpg)
Boren Jan - Novo-Nordisk : Metabolism (2015-2016)
Bruckert Eric A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : Lipid (2015)
- Danone : Lipid (2015)
- Aegerion : Lipid (2015)
- Rottapharm : Lipid (2015)
- Amgen : Lipid (2015-2016)
- Astra Zeneca : Lipid (2015-2016)
- Sanofi Aventis : lipid (2015-2016)
- Lilly : Lipid (2015-2016)
- Chiesi Pharma : Lipid (2015-2016)
- Unilever : Lipid (2015-2016)
- Regeneron : lipid (2015-2016)
- Meda pharma : Lipid (2016)
- Genfit SA : Lipid (2016)
- MSD : Lipid (2016)
- Ionis pharmaceuticals : Lipid (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : lipid (2016)
- Aegerion : Lipid (2016)
D - Research funding (departmental or institutional).- Amgen : Lipid (2015)
- Danone : lipid (2015)
- Aegerion : Lipid (2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 13: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/13.jpg)
Bruckert Eric - Sanofi Aventis : Lipid (2016)
Claeys Marc A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eli Lilly : prasugrel, abciximab (2015-2016)
- Bayer : rivaroxabam (2015-2016)
- Abbott Vascular : stents- mitraclip (2015-2016)
- Astra Zeneca : ticagrelor (2015-2016)
Cordero Alberto A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Advisory Board (2015)
- Sanofi Aventis : Advisory Board (2015)
- Astra Zeneca : Consultancy and Speaker fee (2015)
- Ferrer Spain : Consultancy and Speaker fee (2015)
- Sanofi Aventis : Dyslipidemia (2016)
- Amgen Inc : Dyslipidemia (2016)
Corsini Alberto A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Cardiovascular (2015-2016)
- Astra Zeneca : Cardiovascular (2015-2016)
- Pfizer : Cardiovascular (2015-2016)
- Bristol Myers Squibb : cardiovascular (2015-2016)
- Mediolanum : Cardiovascular (2015-2016)
- Sanofi Aventis : Cardiovascular (2016)
- Recordati International : Cardiovascular (2016)
D - Research funding (departmental or institutional).- Regeneron : cardiovascular (2015-2016)
- Polichem : Cardiovascular (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 14: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/14.jpg)
Corsini Alberto - Rottapharm : Metabolism (2015-2016)
Dingli Philip Nothing to be declared (2015-2016)
Ezhov Marat A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Atherosclerosis (2015-2016)
Faouzi Addad Nothing to be declared (2015-2016)
Ferrieres Jean A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : alirocumab (2015-2016)
- Cerenis therapeutics : Atherosclerosis (2015-2016)
- Amgen : evolocumab (2015-2016)
- Merck Sharp & Dohme : ezetimibe (2015-2016)
- Aegerion : Lomitapide (2016)
Fras Zlatko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : cardiovascular drugs (ivabradine, ACE inhibitors) (2015)
- Mylan : cardiovascular prevention drugs (fenofibrate, simvastatin) (2015)
- Krka Pharma : cardiovascular prevention drugs (statins, ACE inhibitors) (2015)
- Merck Sharp & Dohme : ezetimibe (2015)
- Sanofi Aventis : alirocumab (2015-2016)
- Amgen : evolocumab (2015-2016)
- Astra Zeneca : ticagrelor (2015-2016)
- Boehringer-Ingelheim : empagliflozin (diabetes & CVD) (2016)
E - Research funding (personal).- Duke Clinical Research Institute : alirocumab (2015-2016)
Funck-Brentano Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Intracellular Therapies USA : Cardiac Safety of non-cardiovasclar products (2015)
- Bristol Myers Squibb (USA) : Cardiac safety of antiviral drugs (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 15: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/15.jpg)
Funck-Brentano Christian - Pierre-Fabre : Cardiac Safety of non-cardiovasclar products (2015-2016)
- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2015-2016)
- Janssen Belgium : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2015-2016)
- MMV (CH) : Cardiac Saftey of two antimalarial drugs (2015-2016)
- Banook (CRO) : Data and Safety Monitoring Board for an antibody developed in rheumatology (2015-2016)
Georgiou Georgios C Nothing to be declared (2015-2016)
Giannuzzi Pantaleo Nothing to be declared (2015-2016)
Gudnason Thorarinn Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : NOAC (2015)
Gueyffier Francois D - Research funding (departmental or institutional).- Bristol Myers Squibb : Diabetes (2015-2016)
- Teva Pharmaceutical Industries : Multiple sclerosis (2015-2016)
- Portola Pharmaceuticals : Thrombosis (2015-2016)
- EryTech Pharma : Drugs encapsulated in red cells (2016)
Henkin Yaakov A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : apixaban (2015-2016)
- Merck Sharp & Dohme : Ezetimibe (2015-2016)
- Sanofi Aventis : Praluent (2015-2016)
- Amgen Inc : Repatha (2015-2016)
D - Research funding (departmental or institutional).- Sanofi Aventis : ODYSSEY trial (2015-2016)
Hovland Anders A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Lipid Lowering (2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 16: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/16.jpg)
Hovland Anders - Sanofi Aventis : Lipid Lowering (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Lipid Lowering (2015)
- Sanofi Aventis : Lipid lowering (2015)
D - Research funding (departmental or institutional).- Amgen : Lipid lowering (2016)
Ibrahimi Pranvera Nothing to be declared (2015-2016)
Ibrahimov Firdovsi Nothing to be declared (2015-2016)
Ivanov Victoria Nothing to be declared (2015-2016)
Kayikcioglu Meral B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : cardiovascular (2015-2016)
- Pfizer : cardiovascular (2015-2016)
- Sanofi Aventis : cardiovascular (2015-2016)
- Genzyme : cardiovascular (2015-2016)
- Amgen : pcsk-9 (2015-2016)
- Aegerion : lomitapide for homozygous hypercholesterolemia (2016)
Kedev Sasko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : Speaker fees (2015-2016)
- Medtronic : Speaker fees (2015-2016)
- Terumo Inc : Speaker fees (2015-2016)
- Meril : Speaker fees (2015-2016)
Kervinen Kari A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Acute coronary syndrome (2015)
- Abbott : MitraClip (2015)
- Amgen : Hyperlipidemia (2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 17: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/17.jpg)
Kervinen Kari B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : Interventional Cardiology (2016)
Kintscher Ulrich A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Anti-thrombotic therapy and Anti-dyslipidemia therapy (2015)
- Berlin Chemie AG : Hypertension (2015-2016)
- Sanofi Aventis : Dyslipidemia (2016)
D - Research funding (departmental or institutional).- Bayer : Heart Failure (2015)
Kiss Robert Gabor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : apixaban (2015)
- Boehringer-Ingelheim : dabigatran (2015)
- Bayer Healthcare : rivaroxaban (2015)
- Sanofi Aventis steering committee member : coordination of a PCSK9 study (2016)
- TIMI group steering committee member : diabetes drug therapy (2016)
- Cleveland Clinic Research Foundation : fish oil (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- TIMI group : steering committee member (2015)
- Boehringer-Ingelheim : NOAC (2016)
- Pfizer : NOAC (2016)
- Bayer AG : NOAC (2016)
- MSD : sitagliptin, ezetimibe (2016)
Klausen Ib Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Advisory board (has left) (2015)
- Sanofi Aventis : Advisory board (has left) (2015)
- Astra Zeneca : Speaker (2015-2016)
- MSD : Speaker (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 18: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/18.jpg)
Klausen Ib Christian - Amgen : Speaker (2016)
- Sanofi Aventis : Speaker (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Primary Investigator (2015)
- Astra Zeneca : Primary Investigator (2015)
- Pfizer : Primary Investigator (2015)
- Sanofi Aventis : Primary Investigator (2015)
- MSD : Primary Investigator (2015)
- Astra Zeneca : PI (2016)
- Sanofi Aventis : PI (2016)
- MSD : PI (2016)
- Phizer : PI (2016)
Krstacic Goran Nothing to be declared (2015-2016)
Latkovskis Gustavs A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulants (2015-2016)
- Boehringer-Ingelheim : Anticoagulants (2015-2016)
- Berlin Chemie AG : Antihypertensive agents (2015-2016)
- Sanofi Aventis : Antihypertensive therapies, risk estimation and management, prevention (2015-2016)
- Merck Serono : Beta blockers (2015-2016)
- University of Latvia : Education (2015-2016)
- Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics (2015-2016)
- Siemens Healthcare : hs-troponin I (2015-2016)
- Servier : Hypertension, heart rate (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 19: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/19.jpg)
Latkovskis Gustavs - Latvian Association of Human Genetics : Lecture on familial hypercholesterolemia (2015-2016)
- Mylan : Lipid lowering therapies (2015-2016)
- Astra Zeneca : lipid-lowering drugs, anti platelets (2015-2016)
- Amgen : Lipid-lowering. (2015-2016)
- Riga Stradins University : Postgraduate education (2015-2016)
- Menarini : Antihypertensive therapy (2016)
- Abbott Laboratories : Cardiac markers (2016)
D - Research funding (departmental or institutional).- Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2015-2016)
E - Research funding (personal).- Merck Serono : bisoprolol and amlodipine combination (2015-2016)
- Pharma and Chemistry Competence Centre of Latvia : Statin myopathy (2015-2016)
Lettino Maddalena A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : Statins, ezetimibe (2015)
- Boehringer-Ingelheim : Anticoagulants (2015-2016)
- Aspen : Anticoagulants (2015-2016)
- Pfizer : Anticoagulants, statins (2015-2016)
- Eli Lilly : Antithrombotic agents (2015-2016)
- Daiichi Sankyo : Antithrombotic agents, anticoagulants (2015-2016)
- Bayer Healthcare : Antithrombotic agents, anticoagulants (2015-2016)
- Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2015-2016)
- Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (PCK9 inhibitors) (2015-2016)
- Astra Zeneca : Antithrombotic agents, statins (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 20: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/20.jpg)
Lionis Christos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Pneumococcal vaccination (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Janssen - Cilag Pharmaceutical SACI : Advisory Board fees (topic relevant to common mental disorders) (2015)
- Vianex : Advisory Board fees (topic relevant to vaccinations in adults) (2015)
- Pfizer International Operations : Advisory Board fees (topic relevant to vaccinations in adults) (2015)
D - Research funding (departmental or institutional).- ELPEN S.A. : Observational (eridemiological) Study on metabilic syndrome (2015)
- European Commission, Third Programme for the Union’s action in the field of health (2014-2020) : EUropean Refugees-HUman Movement and Advisory Network (Eur-human) (2016)
- Olvos S.A. : Postmarket evaluation of the effectiveness of the extract preparation of 3 Cretan herbs (Cretan Iama) (2016)
Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : atrial fibrillation (2015)
- Biotronik : atrial fibrillation (2015)
- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2015)
- Daiichi Sankyo : atrial fibrillation, thrombosis (2015)
- Pfizer : atrial fibrillation, thrombosis (2015)
- Bayer Healthcare : atrial fibrillation, thrombosis (2015)
- Bristol Myers Squibb : atrial fibrillation, thrombosis (2015)
- Medtronic : AF screening (2016)
- BMS/Pfizer : Anticoagulation (2016)
- Daiichi-Sankyo : Anticoagulation (2016)
- Boehringer Ingelheim : Anticoagulation (2016)
- Bayer/Janssen : Anticoagulation (2016)
D - Research funding (departmental or institutional).- Daiichi Sankyo : atrial fibrillation, thrombosis (2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 21: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/21.jpg)
Lip Gregory Y H - Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)
- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Mach Francois A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart Failure (2015)
- Menarini : Hypertension (2015)
- Sanofi Aventis : Lipid lowering (2015)
- Merck Sharp & Dohme : Lipid lowering (2015)
- Astra Zeneca : Lipid lowering, Hypertension, Heart Failure (2015)
- Daiichi Sankyo : Lipid lowering, NOAC (2015)
- Pfizer : Lipid lowering, NOAC (2015)
- Bayer : NOAC (2015)
- Boehringer-Ingelheim : NOAC (2015)
- Bristol Myers Squibb : NOAC (2015)
- Amgen : Lipid lowering (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- MSD : lipid lowering (2016)
D - Research funding (departmental or institutional).- Merck Sharp & Dohme : Lipid lowering (2015)
- Amgen : Lipid lowering (2015-2016)
Maher Vincent B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- MSD : Speaker Honararia (2015-2016)
- Servier speaker honoraria : Speaker Honararia (2015-2016)
D - Research funding (departmental or institutional).- Sanofi Aventis : FH Network (2015-2016)
Marques-Vidal Pedro B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Swiss national fund : PhD scholarship (2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 22: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/22.jpg)
Marques-Vidal Pedro D - Research funding (departmental or institutional).- Swiss national fonds : PhD scholarship (2016)
Marzal Domingo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Anticoagulants (2015-2016)
- Pfizer : Anticoagulants (2015-2016)
- Bayer Healthcare : Anticoagulants (2015-2016)
- Bristol Myers Squibb : Anticoagulants (2015-2016)
- Astra Zeneca : Antiplatelets therapy (2015-2016)
- Daiichi Sankyo : Antiplatelets therapy (2015-2016)
- Merck Sharp & Dohme : Dyslipidaemias (2015-2016)
- Novartis : Heart Failure (2015-2016)
- Laboratorios Rovi : Heart Failure (2015-2016)
- Servier : Ischaemic cardiomyopathy (2015-2016)
- Spanish Society of Cardiology : Ischaemic cardiomyopathy (2015-2016)
- Menarini : Ischaemic cardiomypathy (2015-2016)
D - Research funding (departmental or institutional).- Novartis : Heart Failure (2015-2016)
E - Research funding (personal).- Novartis : Heart Failure (2015-2016)
Milicic Davor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Roche Diagnostics : Biomarkers (2015-2016)
- Heartware : LVAD (2015-2016)
- Boehringer-Ingelheim : NOACS (2015-2016)
- Bayer Healthcare : NOACS (2015-2016)
- Amgen : PCSK9 inhibitors (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 23: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/23.jpg)
Milicic Davor - Astra Zeneca : Ticagrelor (2015-2016)
Mirrakhimov Erkin Nothing to be declared (2015-2016)
Mitchenko Olena A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : Dyslipidemia (2015-2016)
Mureddu Gian Francesco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : cardiovascular diagnostic systems (2015-2016)
- Boehringer-Ingelheim : cardiovascular pharmaceutical (2015-2016)
- Servier : cardiovascular pharmaceutical (2015-2016)
- Bayer Healthcare : cardiovascular pharmaceutical (2015-2016)
- Malesci : cardiovascular pharmaceutical (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : cardiovascular pharmaceutical (2015-2016)
Mussagaliyeva Aisulu A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Stable angina (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Stable angina (2015-2016)
Nedeljkovic Milan Nothing to be declared (2015-2016)
Nilsson Lennart Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Lipidology (2015)
- Sanofi Aventis : Lipidology (2015)
- Merck Sharp & Dohme : Lipidology (2015)
Pedro Botet Montoya Juan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Esteve : Alipza (2015)
- Sanofi Aventis : Alirocumab (2015)
- MSD : Inegy, Atozet (2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 24: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/24.jpg)
Pedro Botet Montoya Juan - Mylan : Pravafenix 40/160 (2015)
- Astra Zeneca : Crestor, Forxiga, Xigduo (2016)
- Merck Sharp & Dohme : Inegy, Atozet (2016)
- Sanofi Aventis : Praluent (2016)
- Mylan : Pravafenix (2016)
- Ferrer Internacional : Provisacor, Omacor (2016)
- Amgen : Rephata (2016)
Pella Daniel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : anticoagulant drugs (2015)
- Amgen : dyslipemia (2015)
- Zentiva : dyslipidemia (2015)
- Servier : hypertension, coronary artery disease (2015)
- Merck Sharp & Dohme : dyslipidemia (2015-2016)
- Amgen : dyslipidemia (2016)
- Servier : hypertension, dyslipidemia, coronary artery disease (2016)
- Pfizer : novel oral anticoagulants (2016)
Petriashvili Shalva Nothing to be declared (2015-2016)
Piepoli Massimo Francesco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015-2016)
- Novartis : Heart Failure Prevention Initiatives (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart Failure Prevention Initiatives (2015-2016)
Pojskic Belma A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : alirocumab (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 25: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/25.jpg)
Pojskic Belma B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : alirocumab (2015-2016)
Postadzhiyan Arman A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : ACS (2015-2016)
- Bayer : AF (2015-2016)
- Boehringer-Ingelheim : AF (2015-2016)
- Pfizer : AF, dyslipidemia (2015-2016)
- Amgen : dyslipidemia (2015-2016)
- Sanofi Aventis : dyslipidemia (2015-2016)
Rallidis Loukianos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Hypolipidemic treatment (2015-2016)
- Sanofi Aventis : Hypolipidemic treatment (2015-2016)
Rato Quiteria Agostinho Mateus
Nothing to be declared (2015-2016)
Rigopoulos Angelos Nothing to be declared (2015-2016)
Rosolova Hana A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott Laboratories : antihypetensiva drugs, lipid modifying drug (2015-2016)
- Servier : antihypetensive drugs (2015-2016)
- Mylan : Fenofibrate, Fenofibrate + Ezetimibe, Simvastatin + Fenofibrate (2015-2016)
- Amgen : inhibitors of PCSK9 (2015-2016)
- Merck Sharp & Dohme : lipid modifying drugs - statin, ezetimibe (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : inhibitors of PCSK9 (2015-2016)
Ruschitzka Frank A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Drugs (2015-2016)
- Sanofi Aventis : Drugs (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 26: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/26.jpg)
Ruschitzka Frank - Zoll Medical : LifeVest (2015-2016)
- Heartware : Ventricular assist devices (2015-2016)
- Amgen : Drug (2016)
- Novartis : Drug (2016)
- St. Jude Medical : Medical devices (2016)
- Cardiorentis : TRUE-AHF (2016)
- Cardiorentis : TRUE-AHF Steering Committee (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)
- Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)
- St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)
D - Research funding (departmental or institutional).- Mars : Flavanol-like cocoa products (2015-2016)
Rynkiewicz Andrzej A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : anticoagulants (2015)
- Amgen : hyperlipidemia (2015)
- Sanofi Aventis : hyperlipidemia (2015)
- Servier : hypertension (2015)
- Amgen Inc : hyperlipidemia (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : NOAC (2016)
C - Receipt of royalties for intellectual property.- Servier : arterial hypertension (2016)
D - Research funding (departmental or institutional).- Sanofi Aventis : NOAC (2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 27: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/27.jpg)
Siostrzonek Peter A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Lilly : ACS (2015)
- Astra Zeneca : ACS (2015-2016)
- Boehringer-Ingelheim : Anticoagulation (2015-2016)
- Novartis : heart failure (2015-2016)
- Amgen : lipid (2015-2016)
- Sanofi Aventis : Lipid (2015-2016)
- Servier : SCA (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Lilly : ACS (2015)
- Novartis : heart failure (2015-2016)
Slapikas Rimvydas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : INFLAMMATION (2015-2016)
- Amgen : lipids (2015-2016)
- Sanofi Aventis : LIPIDS (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : INFLAMMATION (2015-2016)
- Amgen : LIPIDS (2015-2016)
- Sanofi Aventis : LIPIDS (2015-2016)
Sujayeva Volha Nothing to be declared (2015-2016)
Tunon Fernandez Jose A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : New lipid lowering drugs PCSK9 inhibitors (2015-2016)
Viigimaa Margus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart failure (2015-2016)
- Boehringer-Ingelheim : Hypertension (2015-2016)
- Menarini : Hypertension (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 28: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/28.jpg)
Viigimaa Margus - Sanofi Aventis : Hypertension, dyslipidemia (2015-2016)
- Amgen : Dyslipidemia (2016)
Visser Laurent Nothing to be declared (2015-2016)
Von Eckardstein Arnold A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : dyslipidemia (2015)
- Sanofi Aventis : dyslipidemia (2015)
- Abbott : troponin assays (2015)
- Amgen : PCSK9 inhibitors (2016)
- Sanofi Aventis : PCSK9 inhibitors (2016)
- Merck Sharp & Dohme : Statins and ezitimibe (2016)
Vrablik Michal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : lipid metabolism, CVD prevention (2015-2016)
- Amgen : lipid metabolism, CVD prevention (2015-2016)
- Pfizer : lipid metabolism, CVD prevention (2015-2016)
- Servier : lipid metabolism, CVD prevention (2015-2016)
- Sanofi Aventis : lipid metabolism, CVD prevention (2015-2016)
- Bristol Myers Squibb : lipid metabolism, CVD prevention (2015-2016)
- Genzyme : lipid metabolism, CVD prevention (2015-2016)
- Merck Sharp & Dohme : lipid metabolism, CVD prevention (2015-2016)
- Mylan : lipid metabolism (2016)
D - Research funding (departmental or institutional).- Pfizer : cardiovascular (2015-2016)
Wald David Nothing to be declared (2015-2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 29: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/29.jpg)
Weiss Thomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Amelior (2015-2016)
- Astra Zeneca : Antithrombotics (2015-2016)
- Boehringer-Ingelheim : doacs (2015-2016)
- Vifor International : Ferrinject (2015-2016)
- Daiichi Sankyo : Sevikar (2015-2016)
- Medtronic : Simplicity System (2015-2016)
D - Research funding (departmental or institutional).- Astra Zeneca : ACS research (2015-2016)
- Daiichi Sankyo : Hypertension Research (2015-2016)
- Medtronic : hypertension research (2015-2016)
Williams Bryan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Hypertension (2015-2016)
- Daiichi Sankyo : Hypertension (2015-2016)
- Novartis : Hypertension (2015-2016)
- Servier : Hypertension (2015-2016)
- Vascular Dynamics USA : Carotid baroreceptor stent - Advisor and will be Chief Investigator for a pivotal international study in resistant hypertension (2016)
Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet therapy (2015)
- Daiichi Sankyo : Antiplatelet therapy (2015)
- Boston Scientific : Complex PCI (2015)
- Sanofi Aventis : Managing Dyslipidemia (2015)
D - Research funding (departmental or institutional).- Sorin Group : Electrophysiology (2015)
- Biotronik : Electrophysiology (2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 30: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/30.jpg)
Windecker Stephan - Johnson & Johnson : Electrophysiology and PCI (2015)
- Guerbet : Imaging (2015)
- Medicines Company : IMP (2015)
- St Jude Medical : PCI (2015)
- Medtronic : Structural Heat Disease (2015)
- Novartis : IMP (2015-2016)
- Actelion : IMP (2015-2016)
- Merck Sharp & Dohme : IMP (2015-2016)
- Abbott : PCI and Structural Heart Disease (2015-2016)
- Boston Scientific : Structural Heart Disease (2015-2016)
- Edwards Lifesciences : Structural Heart Disease (2015-2016)
- Symetis SA : Structural Heart Disease (2015-2016)
- Astrazeneca : Antiplatelet therapy (2016)
- Biotronik : Elektrophysiology (2016)
- Amgen : General Cardiology (2016)
- Takeda Pharmaceuticals : General Cardiology (2016)
- Bristol Myers Squibb : General Cardiology (2016)
- Bayer AG : General Cardiology (2016)
- Biotest : General Cardiology (2016)
- Comed : General Cardiology (2016)
- Baxalta : General Cardiology (2016)
- Medicure : General Cardiology (2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 31: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/31.jpg)
Windecker Stephan - Sanofi Aventis : Heart Failure, General Cardiology (2016)
- Qvanteq : Invasive Cardiology, PCI (2016)
- St. Jude Medical : PCI (2016)
- Medtronic : Structural Heart Disease (2016)
- NVT AG : Structural Heart Disease (2016)
- Quintiles : Structural Heart Disease & PCI (2016)
Wittekoek Janneke A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- LEEFH foundation (cascadescreening FH in the Netherlands) : prevention (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- KPN : e-health (2015-2016)
- Amgen : prevention (2015-2016)
- Philips : prevention (2015-2016)
- MSD : prevention (2016)
Zavatta Marco Nothing to be declared (2015-2016)
Zelveian Parounak A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2015-2016)
- Egis Pharma : Hypertension (2015-2016)
- Pfizer : Hypertension & Atheroclerosis (2015-2016)
- Krka Pharma : Hypertension & Atheroclerosis (2015-2016)
- Takeda Pharmaceuticals : Hypertension (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Krka Pharma : Hypertension (2016)
Zimlichman Reuven Nothing to be declared (2015)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 32: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/32.jpg)
Zimlichman Reuven A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pharmaclinical : Clinical research organization (CRO) (2016)
25/08/2016
Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 33: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/33.jpg)
Aboyans Victor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antithrombotics (2014)
- Novartis : Hypertension (2014-2015)
- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)
- Sanofi Aventis : Hyperlipidemia (2014-2015-2016)
- Bayer Healthcare : Oral anticoagulation (2014-2015-2016)
- Pfizer/BMS alliance : Oral anticoagulation (2014-2015-2016)
- MSD : Antiplatelet therapy (2016)
- Astrazeneca : Antiplatelet therapy (2016)
- AbbiVie : cachexia (2016)
- Novartis : Heart Failure (2016)
Achenbach Stephan Nothing to be declared (2015-2016)
D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2014)
Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Thermo Fischer Scientific : Cardiac markers (2014-2015)
- Astra Zeneca : Platelet inhibition (2014-2015)
- Vifor International : Heart failure (2015)
- Astra Zeneca : Antiplatelet treatment (2016)
Badimon Lina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- MSD-España : Lipids (2014)
- Sanofi Aventis : lipids (2014-2015-2016)
- Burson Masteller : nutrition (2014-2015-2016)
- Astra Zeneca : thrombosis (2014-2015-2016)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 34: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/34.jpg)
Badimon Lina D - Research funding (departmental or institutional).- Astrazeneca : thrombosis (2014-2015-2016)
Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Anticoagulation (2014-2015-2016)
- Daiichi Sankyo : Anticoagulation (2014-2015-2016)
- Pfizer : Anticoagulation (2014-2015-2016)
- Bayer : Anticoagulation (2014-2016)
- Merck Sharp & Dohme : Dyslipemia (2015-2016)
Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Direct Flow Medical : transcatheter valve implantation (2014-2015)
- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2014-2015-2016)
- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016)
- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016)
- Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016)
- Gore : Occluders for shunt closure (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Direct Flow Medical : transcatheter valve implantation (2014-2015)
- Actelion : Bosentan for PAH treatment in congenital heart disease (2014-2015-2016)
- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016)
- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016)
- Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016)
- Gore : Occluders for shunt closure (2015-2016)
Bax Jeroen Nothing to be declared (2014-2015-2016)
Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Aspirin, rivaroxaban (2014)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 35: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/35.jpg)
Bueno Hector - Menarini : Ranolazine (2014)
- Novartis : Serelaxin (2014)
- Sanofi Aventis : Clopidogrel (2014-2015)
- Daiichi Sankyo : Prasugrel (2014-2015)
- Eli Lilly : Prasugrel (2014-2015)
- Pfizer : Apixaban (2014-2015-2016)
- Bristol Myers Squibb : Apixaban (2014-2015-2016)
- Servier : ivabradine (2014-2015-2016)
- Astra Zeneca : Ticagrelor (2014-2015-2016)
- Bayer Healthcare : Aspirin (2015)
- Novartis : Serelaxin, LCZ696 (2015)
- Ferrer Internacional : Trinomia (polypill) (2015-2016)
- Janssen-Cilag : GEMINI Trial - RIVAROXACS2002 (2016)
- Novartis : Serelaxin, LCZ696, ACZ885, AHF Academy (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Ticagrelor (2015-2016)
E - Research funding (personal).- Astra Zeneca : Ticagrelor (2014-2015-2016)
Carerj Scipione Nothing to be declared (2014-2015-2016)
Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2014-2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2014-2015-2016)
Fitzsimons Donna Nothing to be declared (2016)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 36: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/36.jpg)
Fitzsimons Donna A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)
- Amgen : lipid management (2015)
Gaemperli Oliver Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)
- Abbott Vascular : MitraClip (2015)
- Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : cardiovascular (2014)
- Pfizer : cardiovascular (2014)
- Bristol Myers Squibb : cardiovascular (2014)
- Medtronic : cardiovascular (2014-2015)
- St Jude Medical : cardiovascular (2014-2015)
- Sanofi Aventis : cardiovascular (2014-2015)
- Meda pharma : cardiovascular (2014-2015)
- Merck Sharp & Dohme : cardiovascular (2014-2015)
- Medscape : cardiovascular (2014-2015)
- Boehringer-Ingelheim : cardiovascular (2014-2015-2016)
- Astra Zeneca : cardiovascular (2015)
- Servier : cardiovascular (2015)
- Bayer Vital : cardiovascular (2015)
- Correvio : cardiovascular (2015)
- Bristol Myers Squibb Global : cardiovascular (2015)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 37: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/37.jpg)
Kirchhof Paulus - Pfizer Germany : cardiovascular (2015)
- Bayer Healthcare : cardiovascular (2015-2016)
- Daiichi Sankyo Europe : cardiovascular (2015-2016)
- Pfizer Global : cardiovascular (2015-2016)
D - Research funding (departmental or institutional).- Meda pharma : cardiovascular (2014-2015)
- Daiichi Sankyo : cardiovascular (2014-2015-2016)
- St Jude Medical : cardiovascular (2014-2015-2016)
- Sanofi Aventis : cardiovascular (2014-2015-2016)
- British Heart Foundation : cardiovascular (2014-2015-2016)
- BMS / Pfizer alliance : cardiovascular (2014-2015-2016)
- Leducq Foundation : cardiovascular (2014-2015-2016)
- European Union FP7 : cardiovascular (2014-2015-2016)
- European Union horizon2020 : cardiovascular (2014-2015-2016)
- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015-2016)
- UK Medical Research Council : cardiovascular (2015-2016)
Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet agents (2014-2015-2016)
- B.Braun : Surgical instruments (2014-2015-2016)
D - Research funding (departmental or institutional).- Medtronic : Cardiac valves (2014-2015)
- Edwards Lifesciences : Cardiac valves (2014-2015-2016)
Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : nebivolol (2014)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 38: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/38.jpg)
Lancellotti Patrizio - Servier : Imaging Ischemic disease (2015)
- Boston Scientific : Sudden death (2015)
- St Jude Medical : Echo course (2015-2016)
- Servier : Ischemic Heart Disease (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : CRT (2014)
- Servier : procoralan (2014)
- Bayer : NOAC (2015-2016)
Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : atrial fibrillation (2014-2015)
- Biotronik : atrial fibrillation (2014-2015)
- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)
- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
- Pfizer : atrial fibrillation, thrombosis (2014-2015)
- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)
- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)
- Medtronic : AF screening (2016)
- BMS/Pfizer : Anticoagulation (2016)
- Daiichi-Sankyo : Anticoagulation (2016)
- Boehringer Ingelheim : Anticoagulation (2016)
- Bayer/Janssen : Anticoagulation (2016)
D - Research funding (departmental or institutional).- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
- Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 39: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/39.jpg)
Lip Gregory Y H - Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Nihoyannopoulos Petros Nothing to be declared (2014-2015-2016)
Piepoli Massimo Francesco Nothing to be declared (2014)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015-2016)
- Novartis : Heart Failure Prevention Initiatives (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart Failure Prevention Initiatives (2015-2016)
Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : acute coronary syndrome (2014)
- Boehringer-Ingelheim : anticoagulant (2014)
- Respicardia : anticoagulant (2014)
- Johnson & Johnson : heart failure (2014)
- Pfizer : heart failure, anticoagulant (2014)
- MSD : lipids (2014)
- Abbott Vascular : devices (2014-2015)
- Bayer Healthcare : heart failure (2014-2015)
- CIBIEM : heart failure (2014-2015)
- Novartis : heart failure (2014-2015-2016)
- Cardiorentis : heart failure (2014-2015-2016)
- Vifor Pharma ltd : heart failure (2014-2015-2016)
- Servier : heart failure, coronary artery disease (2014-2015-2016)
- Amgen : heart failure, lipids (2014-2015-2016)
- BioControl : devices (2015)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 40: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/40.jpg)
Ponikowski Piotr - DC Device : devices (2015)
- Celladon : heart failure (2015)
- Pfizer : lipids (2015)
- Boehringer-Ingelheim : anticoagulant, diabetes (2015-2016)
- Respicardia : devices (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : acute coronary syndrome (2014)
- Vifor Pharma ltd : heart failure (2014)
- MSD : lipids (2014)
- Amgen : heart failure, lipids (2014-2015)
- Respicardia : anticoagulant (2014-2015-2016)
- Novartis : heart failure (2014-2015-2016)
- Cardiorentis : heart failure (2014-2015-2016)
- Bayer Healthcare : heart failure (2014-2015-2016)
- CIBIEM : heart failure (2014-2015-2016)
- Servier : heart failure, coronary artery disease (2014-2015-2016)
- Celladon : heart failure (2015)
- BioControl : devices (2015-2016)
- DC Device : devices (2015-2016)
Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Johnson & Johnson : coronary catheters (2014-2015-2016)
- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)
- Terumo Inc : coronary catheters (2016)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 41: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/41.jpg)
Roffi Marco D - Research funding (departmental or institutional).- Biosensors : devices (2014-2015-2016)
- Boston Scientific : devices (2014-2015-2016)
- Medtronic : devices (2014-2015-2016)
- Biotronik : devices (2014-2015-2016)
- Abbott Vascular : devices (2014-2015-2016)
- Terumo Inc : devices (2015-2016)
Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)
- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)
- Lilly : pulmonary arterial hypertension - ambrisentan (2014)
- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015-2016)
- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2014-2015-2016)
- Teva Pharmaceutical Industries : anti-cancer treatment (2015-2016)
- Sanofi Aventis : anticoagulants (2015-2016)
- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015-2016)
- United Therapeutics : pulmonary hypertension (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Pulmonary hypertension (2014-2015-2016)
Vaz Carneiro Antonio Nothing to be declared (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AbbVie : Oncology (2014)
Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eli Lilly : Antiplatelet therapy (2014)
- Bayer Healthcare : Antithrombotic drug (2014)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 42: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/42.jpg)
Windecker Stephan - Abbott : Stent and Heartvalvetherapy (2014)
- Biosensors : Stents (2014)
- Boston Scientific : Stents (2014)
- Astra Zeneca : Antiplatelet therapy (2014-2015)
- Daiichi Sankyo : Antiplatelet therapy (2015)
- Boston Scientific : Complex PCI (2015)
- Sanofi Aventis : Managing Dyslipidemia (2015)
D - Research funding (departmental or institutional).- Medicines Company : Antithrombotic therapy (2014)
- Johnson & Johnson : Catheters (2014)
- Edwards Lifesciences : Heartvalves (2014)
- St Jude Medical : OCT (2014)
- Abbott : Stent (2014)
- Biotronik : Stent (2014)
- Boston Scientific : Stent and Heartvalves (2014)
- Medtronic : Stent and Heartvalves (2014)
- Sorin Group : Electrophysiology (2015)
- Biotronik : Electrophysiology (2015)
- Johnson & Johnson : Electrophysiology and PCI (2015)
- Guerbet : Imaging (2015)
- Medicines Company : IMP (2015)
- St Jude Medical : PCI (2015)
- Medtronic : Structural Heat Disease (2015)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 43: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/43.jpg)
Windecker Stephan - Novartis : IMP (2015-2016)
- Actelion : IMP (2015-2016)
- Merck Sharp & Dohme : IMP (2015-2016)
- Abbott : PCI and Structural Heart Disease (2015-2016)
- Boston Scientific : Structural Heart Disease (2015-2016)
- Edwards Lifesciences : Structural Heart Disease (2015-2016)
- Symetis SA : Structural Heart Disease (2015-2016)
- Astrazeneca : Antiplatelet therapy (2016)
- Biotronik : Elektrophysiology (2016)
- Amgen : General Cardiology (2016)
- Takeda Pharmaceuticals : General Cardiology (2016)
- Bristol Myers Squibb : General Cardiology (2016)
- Bayer AG : General Cardiology (2016)
- Biotest : General Cardiology (2016)
- Comed : General Cardiology (2016)
- Baxalta : General Cardiology (2016)
- Medicure : General Cardiology (2016)
- Sanofi Aventis : Heart Failure, General Cardiology (2016)
- Qvanteq : Invasive Cardiology, PCI (2016)
- St. Jude Medical : PCI (2016)
- Medtronic : Structural Heart Disease (2016)
- NVT AG : Structural Heart Disease (2016)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
![Page 44: Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE · 2016. 8. 26. · - Recordati International : Cardiovascular (2015-2016) - Amgen Inc : Cardiovascular (2016) ... - Merck Sharp](https://reader031.fdocuments.us/reader031/viewer/2022012007/610b08f6d5d176494856bce1/html5/thumbnails/44.jpg)
Windecker Stephan - Quintiles : Structural Heart Disease & PCI (2016)
Zamorano Gomez Jose Luis
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Philips : 3D echo (2014)
- Toshiba medical imaging : fusion imaging 3D echo CT (2014)
- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)
- MSD : CV risk factors (2014-2015)
- Abbott : Lecturing (2015)
- Pfizer : Lecturing (2015)
- Sorin Group : Respicardia echo protocol (2015)
- Philips : 3D Echocardiography. (2016)
- Servier : Clinical case presentation during ESC Cong 2016 (2016)
- Pfizer : speaker CV risk factors. (2016)
- MSD : speaker. CV risk factors (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Siemens Healthcare : 3d echo software and free style echo (2014-2015)
- Toshiba medical imaging : Fusion Imaging (2015)
D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)
- Novartis : Clinical trial (2014-2015)
- Ikaria : Clinical trial (2014-2015)
- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)
- Abbott : Epidemiology study of Mitral regurgitation (2016)
25/08/2016
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.